TG Therapeutics Inc

TG Therapeutics Inc

TGTX

Get informed when a big investor buys or sells

+ Follow
Market Cap$5.81B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
TG Therapeutics IncTG Therapeutics Inc11.9-79%100.1
$70.00

Target Price by Analysts

74.5% upsideTG Therapeutics Target Price DetailsTarget Price
$0.44

Current Fair Value

98.9% downside

Overvalued by 98.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$5.81 Billion
Enterprise Value$5.40 Billion
Dividend Yield$- (-)
Earnings per Share$3.1
Beta1.68
Outstanding Shares144,439,370

Return

Return on Equity79.21%ROE
Return on Assets30.21%
Return on Invested Capital11.68%

Valuation & Multiples

P/E Ratio11.86P/E Ratio
PEG4.08PEG
Price to Sales10.03Price to Sales
Price to Book Ratio10.03Price to Book Ratio
Enterprise Value to Revenue7.71
Enterprise Value to EBIT34.45
Enterprise Value to Net Income11
Total Debt to Enterprise0.01
Debt to Equity0.06Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 11, 2026
EPS Estimate
$0.28
Average shareholder expectation
Revenue Estimate
$198.14 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 3, 2026
EPS Estimate
$0.38
Average shareholder expectation
Revenue Estimate
$226.55 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.2208▼ 11.92%
Total Calls1,912,300▲ 15.69%
Total Puts2,334,600▲ 5.40%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %73.01%▲ 2.11%
Total Invested$3.50B▲ 13.83%
Investors Holding382▲ 14.00%

ESG Score

No data

About TG Therapeutics Inc

CEO: Michael Weiss